New positive clinical results from ViiV’s (GSK) two-drug HIV therapy

ViiV, a subsidiary of GSK’s, yesterday evening announced results from the Phase III clinical trial Flair, assessing the efficacy of its two-drug (cabotegravir, rilpivirine) therapy on HIV patients. Specifically, the results show that the two-drug regime has the same efficacy as the conventional three-drug treatment Triumeq at 48 treatment weeks. The new regime’s advantage is its once-monthly intramuscular injection, while the conventional therapy requires to take the three drugs daily.

(Source: GSK)